Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 3
1988 2
1990 1
1993 1
1995 2
1996 2
1997 2
1998 1
2000 1
2002 3
2003 5
2004 2
2007 1
2008 2
2009 1
2010 3
2011 1
2012 1
2013 1
2014 2
2016 2
2017 1
2018 2
2019 1
2020 4
2021 1
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

44 results
Results by year
Filters applied: . Clear all
Page 1
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Ladenstein R, et al. Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442501 Clinical Trial.
In this component of the trial, patients were randomly assigned (1:1) to receive dinutuximab beta (20 mg/m(2) per day as an 8 h infusion for 5 consecutive days) or dinutuximab beta plus subcutaneous IL-2 (6 10(6) IU/m(2) per day on days 1-5 and days 8-12 of each cycle) wit …
In this component of the trial, patients were randomly assigned (1:1) to receive dinutuximab beta (20 mg/m(2) per day as an 8 h infusion
A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.
Szebeni J, Bedőcs P, Csukás D, Rosivall L, Bünger R, Urbanics R. Szebeni J, et al. Adv Drug Deliv Rev. 2012 Dec;64(15):1706-16. doi: 10.1016/j.addr.2012.07.005. Epub 2012 Jul 20. Adv Drug Deliv Rev. 2012. PMID: 22820530 Review.
Intravenous administration of low (milligram) doses of nanoparticulate materials in pigs can lead to acute cardiopulmonary, hemodynamic, hematological, biochemical and dermatological changes within minutes, mimicking the human infusion (or anaphylactoid) reaction
Intravenous administration of low (milligram) doses of nanoparticulate materials in pigs can lead to acute cardiopulmonary, hemodynam …
Management of cisplatin-associated toxicities in bladder cancer patients.
Desilets A, Adam JP, Soulières D. Desilets A, et al. Curr Opin Support Palliat Care. 2020 Sep;14(3):286-292. doi: 10.1097/SPC.0000000000000505. Curr Opin Support Palliat Care. 2020. PMID: 32740273 Review.
PURPOSE OF REVIEW: Cisplatin remains the treatment cornerstone for bladder cancer, either in neoadjuvant or in metastatic (cisplatin-gemcitabine or dose-dense methotrexate, vinblastine, and doxorubicin). Timely and adequate management of cisplatin's adverse events i …
PURPOSE OF REVIEW: Cisplatin remains the treatment cornerstone for bladder cancer, either in neoadjuvant or in metastatic (cisplatin-gemcita …
Acute cardiac toxicity in patients after doxorubicin treatment and the effect of combined tocopherol and nifedipine pretreatment.
Lenzhofer R, Ganzinger U, Rameis H, Moser K. Lenzhofer R, et al. J Cancer Res Clin Oncol. 1983;106(2):143-7. doi: 10.1007/BF00395393. J Cancer Res Clin Oncol. 1983. PMID: 6630285 Clinical Trial.
In two groups of female patients with metastatic breast cancer who had all been pretreated with doxorubicin (350 mg/m2), acute cardiac effects following i.v. doxorubicin bolus injection (60 mg/m2) were recorded on the basis of systolic time intervals (STI). . …
In two groups of female patients with metastatic breast cancer who had all been pretreated with doxorubicin (350 mg/m2), acute
Brentuximab Vedotin Infusion Reaction Management: A Case Study.
Comer H, Cardwell K. Comer H, et al. J Adv Pract Oncol. 2017 Sep-Oct;8(6):626-629. Epub 2017 Sep 1. J Adv Pract Oncol. 2017. PMID: 30310723 Free PMC article. Review.
Acute infusion reaction management and subsequent premedication strategies are outlined. ...With the institution of the outlined premedications, Ms. R tolerated subsequent infusions well, at full dose and at standard infusion rates, with no docu
Acute infusion reaction management and subsequent premedication strategies are outlined. ...With the institution of the
Safety aspects of pegylated liposomal doxorubicin in patients with cancer.
Alberts DS, Garcia DJ. Alberts DS, et al. Drugs. 1997;54 Suppl 4:30-5. doi: 10.2165/00003495-199700544-00007. Drugs. 1997. PMID: 9361959 Review.
Other adverse effects included nausea and vomiting and alopecia. Acute hypersensitivity infusion reactions have been reported in up to 9% of patients in some studies. Recently published data from a phase II trial in patients with refractory ovarian cancer sho …
Other adverse effects included nausea and vomiting and alopecia. Acute hypersensitivity infusion reactions have been re …
From conventional to stealth liposomes: a new frontier in cancer chemotherapy.
Cattel L, Ceruti M, Dosio F. Cattel L, et al. Tumori. 2003 May-Jun;89(3):237-49. doi: 10.1177/030089160308900302. Tumori. 2003. PMID: 12908776 Review.
Pegylated liposomal doxorubicin is characterized by a very long-circulation half-life, favorable pharmacokinetic behavior and specific accumulation in tumor tissues. ...Pegylated liposomal doxorubicin also appeared to be less myelotoxic than doxorubicin. Typi …
Pegylated liposomal doxorubicin is characterized by a very long-circulation half-life, favorable pharmacokinetic behavior and specifi …
Acute hypersensitivity reactions to etoposide in a VEPA regimen for Hodgkin's disease.
Hudson MM, Weinstein HJ, Donaldson SS, Greenwald C, Kun L, Tarbell NJ, Humphrey WA, Rupp C, Marina NM, Wilimas J, et al. Hudson MM, et al. J Clin Oncol. 1993 Jun;11(6):1080-4. doi: 10.1200/JCO.1993.11.6.1080. J Clin Oncol. 1993. PMID: 8501494
The reactions occurred at a median time of 5 minutes (range, 3 to 120) from the start of the etoposide infusion. ...Three patients who had isolated episodes of hypotension on completion of the etoposide infusion successfully received subsequent infusions
The reactions occurred at a median time of 5 minutes (range, 3 to 120) from the start of the etoposide infusion. ...Three pati …
Monoclonal antibodies in the treatment of cancer, Part 2.
Cersosimo RJ. Cersosimo RJ. Am J Health Syst Pharm. 2003 Aug 15;60(16):1631-41; quiz 1642-3. Am J Health Syst Pharm. 2003. PMID: 12966906 Review.
Gemtuzumab ozogamicin is an active second-line therapy in older patients with acute myelogenous leukemia, but its role in combination regimens is unclear. ...The most common adverse effects of monoclonal antibodies are myelosuppression, infusion-related reactions
Gemtuzumab ozogamicin is an active second-line therapy in older patients with acute myelogenous leukemia, but its role in combination …
Monoclonal antibodies in the treatment of cancer, Part 1.
Cersosimo RJ. Cersosimo RJ. Am J Health Syst Pharm. 2003 Aug 1;60(15):1531-48. doi: 10.1093/ajhp/60.15.1531. Am J Health Syst Pharm. 2003. PMID: 12951753 Review.
Gemtuzumab ozogamicin is an active second-line therapy in older patients with acute myelogenous leukemia, but its role in combination regimens is unclear. ...The most common adverse effects of monoclonal antibodies are myelosuppression, infusion-related reactions
Gemtuzumab ozogamicin is an active second-line therapy in older patients with acute myelogenous leukemia, but its role in combination …
44 results